Qlife Holding Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Thomas Warthoe

Algemeen directeur

SEK 1.9m

Totale compensatie

Percentage CEO-salaris	98.9%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thomas Warthoe's beloning veranderd ten opzichte van Qlife Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 161m
Jun 30 2024	n/a	n/a	-SEK 142m
Mar 31 2024	n/a	n/a	-SEK 152m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 160m
Sep 30 2023	n/a	n/a	-SEK 85m
Jun 30 2023	n/a	n/a	-SEK 97m
Mar 31 2023	n/a	n/a	-SEK 95m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 93m
Sep 30 2022	n/a	n/a	-SEK 69m
Jun 30 2022	n/a	n/a	-SEK 62m
Mar 31 2022	n/a	n/a	-SEK 60m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 39m
Sep 30 2021	n/a	n/a	-SEK 33m
Jun 30 2021	n/a	n/a	-SEK 23m
Mar 31 2021	n/a	n/a	-SEK 15m
Dec 31 2020	SEK 1m	n/a	-SEK 20m
Sep 30 2020	n/a	n/a	-SEK 37m
Jun 30 2020	n/a	n/a	-SEK 37m
Mar 31 2020	n/a	n/a	-SEK 38m
Dec 31 2019	SEK 1m	n/a	-SEK 32m

Compensatie versus markt: De totale vergoeding ($USD 172.71K ) Thomas } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 478.33K ).

Compensatie versus inkomsten: De vergoeding van Thomas is gestegen terwijl het bedrijf verliesgevend is.

CEO

Thomas Warthoe (57 yo)

4.8yrs

Tenure

SEK 1,881,000

Compensatie

Mr. Thomas Warthoe founded Atonomics A/S in 2000 and also serves as its Chief Executive Officer. He is a Co-Founder of Qlife Holding AB (publ) and serves as it's Chief Executive Officer. He has been a Dire...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Warthoe	Co-Founder	4.8yrs	SEK 1.88m	0.030% € 147.9
Lars Bangsgaard	Independent Chairman	1.8yrs	SEK 175.00k	0.024% € 116.8
Mikael Persson	Independent Director	3.5yrs	SEK 107.00k	0.012% € 60.6
Lars Wegner	Independent Director	1.8yrs	SEK 88.00k	geen gegevens
Jan Lisby	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4HG0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Qlife Holding Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Recent updates

Third quarter 2024 earnings released: kr0.006 loss per share (vs kr27.66 loss in 3Q 2023)

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

Second quarter 2024 earnings released: kr0.006 loss per share (vs kr98.15 loss in 2Q 2023)

Qlife Participates Research Trial for People Living with PKU and Gets Positive Data

Qlife Starts Clinical Trial in China with First Biomarker on Egoo Health

New major risk - Shareholder dilution

Qlife Holding AB (publ) to Report Q2, 2024 Results on Aug 15, 2024

First quarter 2024 earnings released: kr0.013 loss per share (vs kr0.081 loss in 1Q 2023)

Qlife Holding AB (publ) has completed a Composite Units Offering in the amount of SEK 30.150028 million.

Full year 2023 earnings released: kr0.42 loss per share (vs kr5.46 loss in FY 2022)

New major risk - Financial position

Qlife Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 05, 2024

Third quarter 2023 earnings released: kr0.014 loss per share (vs kr1.34 loss in 3Q 2022)

New major risk - Shareholder dilution

New major risk - Revenue size

Second quarter 2023 earnings released: kr0.049 loss per share (vs kr1.30 loss in 2Q 2022)

Qlife Holding AB (publ) announced that it has received SEK 4.647035 million in funding from Pensys Ab, Jinderman & Partners AB

High number of new and inexperienced directors

Full year 2022 earnings released: kr5.46 loss per share (vs kr3.04 loss in FY 2021)

Full year 2022 earnings released: kr4.93 loss per share (vs kr3.83 loss in FY 2021)

Third quarter 2022 earnings released: kr1.34 loss per share (vs kr1.10 loss in 3Q 2021)

Qlife Holding AB (publ) to Report Q3, 2023 Results on Nov 02, 2023

High number of new and inexperienced directors

Second quarter 2022 earnings released: kr1.30 loss per share (vs kr0.85 loss in 2Q 2021)

Qlife Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Develops New, Small, and Disposable Filtration Unit Able to Filtrate Plasma from Whole Blood

First quarter 2022 earnings released: kr0.99 loss per share (vs kr0.60 loss in 1Q 2021)

Full year 2021 earnings released: kr3.83 loss per share (vs kr1.92 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Qlife to Follow Up Danish Clinical Evaluation on Rapid Tests for Covid-19

High number of new and inexperienced directors

Third quarter 2021 earnings released: kr1.13 loss per share (vs kr0.25 loss in 3Q 2020)

Independent Director Niklas Marschall has left the company

Independent Director Niklas Marschall has left the company

Second quarter 2021 earnings released

Full year 2020 earnings released: kr1.92 loss per share (vs kr167 loss in FY 2019)

Qlife Holding AB (Publ) Announces CE Marks Its Covid-19 Test in the Egoo.Health System

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd